Researchers at the University of Pittsburgh have developed a groundbreaking universal receptor system for T cells, featuring a “SNAPtag” that allows for the customization of CAR T cell and other immunotherapies. This innovative method enables T cells to target any cell surface protein by fusing SNAPtag-engineered T cell receptors with antibodies tailored to specific proteins. This flexibility could enhance the effectiveness of treatments for various conditions, including cancer, autoimmune disorders, and organ transplantation. The study, published in Nature Communications, showcases the SNAP approach’s utility in CAR and SynNotch receptors, providing a foundation for personalized therapies. Traditional CAR T cell therapy often struggles when tumors evolve and lose targeted proteins; however, the SNAP system can recognize multiple targets simultaneously, potentially reducing the risk of treatment failure. The SNAP technology employs covalent bonding for receptor activation, significantly enhancing its robustness and efficiency. In preclinical mouse models, SNAP-CAR T cells demonstrated effective tumor reduction and extended survival, paving the way for future clinical trials. The research was supported by various institutions, highlighting its significance in advancing immunotherapeutic strategies.
